MedTrace Logo

Effect of SBG in Patients With Breast Cancer

NCT00533364 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 11

Last updated 2010-02-18

No results posted yet for this study

Summary

This study is set up to determine whether soluble beta-glucan (SBG) has

* unfavourable side effects
* beneficial treatment effects when given in combination with standard antibody and chemotherapy to patients with breast cancer.

Conditions

Interventions

DRUG

SBG (Soluble beta-glucan)

Oral administration, three dose levels, administered day 1-8 in each 3-weeks treatment cycle, 4 treatments cycles.

Sponsors & Collaborators

  • Biotec Pharmacon ASA

    lead INDUSTRY

Principal Investigators

  • Erik Wist, MD, PhD · Ullevaal University Hospital

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-01-31
Primary Completion
2009-08-31
Completion
2010-01-31

Countries

  • Norway

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00533364 on ClinicalTrials.gov